NasdaqGM - Nasdaq Real Time Price USD

Theravance Biopharma, Inc. (TBPH)

Compare

8.78

-0.27

(-2.98%)

At close: January 10 at 4:00:00 PM EST

8.73

-0.05

(-0.57%)

After hours: January 10 at 4:29:04 PM EST

Analysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH)

With the business potentially at an important milestone, we thought we'd take a closer look at Theravance Biopharma...

Simply Wall St. 4 days ago

TBPH
-2.98%
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced that members of its management team will hold investor meetings during the 43rd Annual J.P. Morgan Healthcare Conference, January 13-16, 2025, in San Francisco, CA.

PR Newswire 26 days ago

TBPH
-2.98%
Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 30 days ago

TBPH
-2.98%
IONS
The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable

While it may not be enough for some shareholders, we think it is good to see the Theravance Biopharma, Inc...

Simply Wall St. last month

TBPH
-2.98%
Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference on Tuesday, December 3 at 11:15 am EST (8:15 am PST/4:15 pm GMT) and will be hosting in-person meetings with the investment community at the conference.

PR Newswire last month

TBPH
-2.98%
Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Theravance Biopharma ( NASDAQ:TBPH ) Third Quarter 2024 Results Key Financial Results Revenue: US$16.9m (up 7.5% from...

Simply Wall St. last month

TBPH
-2.98%
Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

TBPH beats third-quarter estimates for both sales and earnings. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

Zacks last month

TBPH
-2.98%
VTRS
Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Theravance Biopharma Inc (TBPH) reports robust quarterly sales growth and outlines strategic plans to enhance shareholder value amidst market challenges.

GuruFocus.com last month

TBPH
-2.98%
Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 40% and 4.71%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

TBPH
-2.98%
Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the third quarter of 2024 and announced the formation of a Strategic Review Committee to assess alternatives to unlock shareholder value.

PR Newswire last month

TBPH
-2.98%
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.

Zacks last month

TBPH
-2.98%
PRTA
-7.84%
AZN
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.

Zacks 2 months ago

^GSPC

MDGL

TBPH
-2.98%
5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.

Zacks 2 months ago

CORT

TBPH
-2.98%
^GSPC
Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its third quarter 2024 financial results and provide a business update after market close on Tuesday, November 12, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm EST (2:00 pm PST/10:00 pm GMT) that day.

PR Newswire 2 months ago

TBPH
-2.98%
Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease

Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced the publication of a sub-study of the pivotal 12-week, randomized, registrational revefenacin Phase 3 trials (Trials 0126 [NCT02459080] and 0127 [NCT02512510]) for YUPELRI, the first and only FDA approved once-daily nebulized long-acting muscarinic antagonist (LAMA), evaluating the area under the curve (AUC) lung function effects in moderate-to-very-severe chronic obstructive pulmonary disease (CO

PR Newswire 2 months ago

TBPH
-2.98%
Seth Klarman's Complete Exit from Theravance Biopharma Inc

On August 31, 2024, The Baupost Group, led by renowned value investor Seth Klarman (Trades, Portfolio), executed a significant transaction by completely exiting its position in Theravance Biopharma Inc (NASDAQ:TBPH). This move has notably reduced the firm's exposure in the biotechnology sector, reflecting a strategic shift or reassessment of the stock's future potential.

GuruFocus.com 3 months ago

TBPH
-2.98%
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 4 months ago

TBPH
-2.98%
Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 4 months ago

TBPH
-2.98%
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks 4 months ago

TBPH
-2.98%
IONS
Seth Klarman's Strategic Reduction in Theravance Biopharma Inc

On July 31, 2024, The Baupost Group, led by renowned value investor Seth Klarman (Trades, Portfolio), executed a significant reduction in its holdings of Theravance Biopharma Inc (NASDAQ:TBPH). This transaction decreased the firm's stake in the company by 29.11%, leaving it with a total of 2,977,304 shares. This move impacted the portfolio by -0.35% and adjusted the firm's position in TBPH to 6.12% of the company's outstanding shares, reflecting a strategic shift in its investment stance.

GuruFocus.com 4 months ago

TBPH
-2.98%

Performance Overview

Return	TBPH	S&P 500
YTD	-7.29%	-1.35%
1-Year	-12.64%	+22.51%
3-Year	-32.25%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Theravance Biopharma, Inc. (TBPH)

Analysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH)

Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference

Theravance Bio (TBPH) Up 3.7% Since Last Earnings Report: Can It Continue?

The past five years for Theravance Biopharma (NASDAQ:TBPH) investors has not been profitable

Theravance Biopharma to Participate in an Upcoming Investor Conference

Theravance Biopharma Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Theravance's Q3 Loss Narrower Than Expected, Revenues Rise Y/Y

Theravance Biopharma Inc (TBPH) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...

Theravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?

Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

5 Small Drug Stocks to Buy as Trump Gets Re-Elected

Theravance Biopharma to Report Third Quarter 2024 Financial Results on November 12, 2024

Theravance Announces Publication of YUPELRI® (revefenacin) Area Under the Curve Spirometry Analysis in the International Journal of Chronic Obstructive Pulmonary Disease

Seth Klarman's Complete Exit from Theravance Biopharma Inc

Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?

Here's Why We're Not At All Concerned With Theravance Biopharma's (NASDAQ:TBPH) Cash Burn Situation

Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?

Seth Klarman's Strategic Reduction in Theravance Biopharma Inc

Performance Overview